UK Clinical Trials Networking Breakfast
 

Ask the Experts 

 

Tuesday 3rd May, 09:30 CEST

Barcelona Science Park (Sala Dolors Aleu)  

Speakers

Dr Linda Magee, OBE

NHS Investment & Health Innovation Specialist - UK Department for International Trade

Linda Magee is the NHS and Health Innovation Sector Specialist for the Healthcare, Life Sciences abd Bio-Economy Cluster in the UK Government's Department for International Trade (DIT). Her role is focused on supporting UK investment leveraging the NHS marketplace, its expertise and associated infrastructure, including clinical trials and evaluation, alongside the wider life sciences and healthcare ecosystem. Previously she was Business Director across the Manchester Academic Health Science Centre (MAHSC) & the Greater Manchester Academic Health Science Network (GMAHSN), now combined within Health Innovation, having been a founding Director of both organisations. She has been a member of the Greater Manchester NIHR Clinical Research Network Steering Group since 2009 with a focus on industry support. Following a PhD in Medical Biochemistry, Linda worked for a US healthcare company in technical and marketing positions, was General Manager of Manchester Bioetch Ltd and Head of Life Sciences, Bionow, Northwest Regional Development Agency. She was awarded an OBE from the Queen in 2009 for her services to biotechnology. 

For further information on her profile and to connect, see here

 

Robert Fabregat

CEO - Biocat (BioRegion of Catalonia)

Robert Fabregat (Barcelona, 1980) has a degree in Chemistry and a PhD in Pharmacy from the University of Barcelona (UB), plus a Masters in Project Management from BES-La Salle.

He was Director General for Research and Innovation in Health for the Catalan Ministry of Health from 2019 to 2021, and Department Head for the same organisation from 2018 to 2019. In October 2021, Robert Fabregat joined Biocat as CEO.

He has extensive experience managing national and international R + I projects in the fields of healthcare and biomedicine, collaborating with various research centers public bodies and private companies. He has also been a professor at the University of Barcelona (UB).

Biocat is the organization that maximises the economic and social impact of the life sciences and healthcare innovation ecosystem in Catalonia. It was created in 2006 by the Government of Catalonia and Barcelona City Council and its goals include: strenghthening its role as an essential agent for boosting the country's research and innovation capacity, helping accelerate the transfer of medical technology and solutions to patients, and consolidating the BioRegion of Catalonia as one of the most important healthcare innovation hubs in Europe.

For further information, please visit Biocat

 

Natalie Wilson

Business Development Manager - NIHR (UK National Institute for Health and Care Research) Clinical Research Network

Natalie Wilson is a Business Development Manager for the NIHR Clinical Research Network ( CRN) and her role is to advise life sciences companies, funders and researchers on the Network's capability and capacity to deliver their research pipeline. She also works closely with the Network's clinicians and managers to provide business development advice. Natalie joined the CRN In 2010 where she worked within the Primary Care as an analyst and industry lead before taking up her current position.

Natalie is an Immunologist by background having completed a PhD in Cancer Inmunotherapy. Following her PhD she spent 9 years running an experimental cancer immunotherapy programme before joining the CRN and now has over 20 years' experience in clinical research.

The National Institute for Health and Care Research (NIHR) Clinical Reserach Network works in partnership with the National Health Service (NHS) to deliver high quality research. We support all phases of clinical research studies and trials across all disease areas. 

For further information, please visit National Institute for Health and Care Research (NIHR)

 

Meri Beckwith

Co- Founder - Lindus Health

Meri Beckwith was previously a venture capital investor and partner to biotech and digital health companies. He took part in the COVID-19 vaccine trials as a volunteer, where he saw how trial outcomes could be improved by focusing on technology ans patient experience.

The mission at Lindus Health is to accelerate clinical trials for biotech and health-tech start-ups, so patients can benefit from new treatment sooner. The clinical trial industry has not changed in 3 years and is dominated by inefficient legacy providers. Lindus conducts entire clinical trials end to end, replacing the need to work with a CRO. We use software and EHR data to help customers design better clinical trials, recruit participants and run a trial efficiently, from electronic data capture, to data management and consenting. 

Our products have been used to recruit, on-board and handle data from thousands of patients across 35 clinical trials and studies, and Lindus Health is currently running 4 clinical trials end to end up to 3 times faster than traditional CROs. 

For further information, please visit  Lindus Health 

 

John McCrae

Chief Technology Officer - North West EHealth

John McCrae has an academic background in mathematics and over 25 years' experience as a Systems Engineer, Database Engineer, and Data Architect working for companies both in the UK and Europe.  He joined NorthWest EHealth in July 0211 as Lead Data Architect for the Salford Lung Study, the world's first pragmatic, randomised phase III real-world effectiveness clinical trial.

As Chief Technology Officer he manages all the technical teams within the company including architecture, data science and statistics, software and database development, business analysis, pharmacovigilance, and IT systems.

He has recently been designated as the Senior Information Risk Officer for NorthWest EHealth and is also a member of several strategy and advisory groups including the Salford Integrated Record Strategy Group and the Discover Now Technical Design Authority.

Relevant papers:

New, John & Leather, David & Diar Bakerly, Nawar & McCrae, John & Gibson, Martin (2018).Putting patients in control of data from electronic heath records. BMJ.360.j5554.10.1136/bmj.j5554

Collier S, Harvey C, Brewster J, et al. Monitoring safety in phase III real effectiveness trial: use of novel methodology in the Salford Lung Study. Pharmacoepidemiology and Drug Safety. 2017 Mar;26(3):344-352. DOI:10.1002/pds.4118.

We like to highlight the following as a case study: https://nweh.co.uk/news/2021/greater-manchester-partners-with-industry-on-pioneering-study-to-test-novel-cholesterol-lowering-treatment-in-the-community

NWEH has developed FARSITE and ConneXon platforms to help support Real World Data driven clinical trials, helping shorten the time period to market authorisation and collecting far more evidence for regulators than a traditional clinical trial.

For further information, please visit NorthWest EHealth Ltd

 

Antonio Vila-Coro

Account Director, Emerging BioPharma - IQVIA

Antonio Vila-Coro is graduated in Pharmacy and PhD in Molecular Biology. Has worked on the development and licensing of non-viral vector based vaccines. Founded and ran the commercial operations of a non-clinical CRO. Currently works at IQVIA biotech as Account Director for Spain and Portugal.

IQVIA, the Human Data Science Company, is a provider of solutions for biopaharmaceutical development and commercialization. IQVIA combines insights, technology, and expertise to maximise the probability of success in a comples and competitive healthacare environment.

For further information, please visit IQVIA UK

 

Jonathan Wogel

Chief Executive Officer (CEO) - NorthWest EHealth

Jonathan has 35 years of global pharma, device & biotech M&A, JV, licensing and scale up experience of 26 years overseas. He developed over £4 billion pounds in M&A deals for private and PE backed businesses and launched and/or licensed over 50 products globally.

The last 10 years he spent focusing on helping SMEs & start-ups with seed/Series A & B VC/Angel & PE based fundraising, business and commercial strategy & scale-ups. 

Jonathan has an underground degree in Biochemistry; MBA, MPH & PhD (Health Economics). He is an Executive Chair/Director of Zentraxa (biomaterials spin out, Bristol University).

For further information, please visit NorthWest EHealth Ltd